Von Bruchhausen, V.; Lohmann, H.; Osvath, J. published the article 《The pharmacokinetic profile of pyrazinobutazone in man》. Keywords: pyrazinobutazone formulation pharmacokinetics.They researched the compound: Sodium 4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-ide( cas:129-18-0 ).SDS of cas: 129-18-0. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:129-18-0) here.
The rate of absorption of phenylbutazone (I) [50-33-9] from pyrazinobutazone [4985-25-5] capsules was lower than that from I capsules. The capsules were bioequivalent to an equimolar dose of Na phenylbutazone [129-18-0] in solution, as judged by both the area under the plasma level curves and the sum of the unchanged I excreted in the urine. A single dose of 300 mg pyrazinobutazone produced maximum plasma levels of 35.2 μg/mL at 5.5 h after administration. Two dosage schedules for long-term therapy were tested (2400 and 1500 mg/wk). Both produced accumulation to saturation plasma levels within approx. 3 days. The concentration of I obtained with the lower dosage was about 110 μg/mL plasma. This corresponded with the recommendations for long-term therapy with I. With the higher dosage, the plasma levels were elevated by only 25%, however, the renal elimination of unchanged drug and the number of side-effects were remarkably increased. The recommended dosage scheme is specifically adapted to the pharmacokinetics of pyrazinobutazone.
Different reactions of this compound(Sodium 4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-ide)SDS of cas: 129-18-0 require different conditions, so the reaction conditions are very important.
Reference:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem